KIF20A and central nervous system cancer: Furthermore, pilot studies, such as those conducted by Fujiwara et al. and Ryogo Kikuchi et al., evaluating KIF20A-targeting vaccines in conjunction with chemotherapy for advanced gastric cancer and high-grade glioma, respectively, have demonstrated manageable safety profiles and suggested potential therapeutic efficacy [99,100].